Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

DBS Sticks to Their Hold Rating for Wuxi Biologics (Cayman) (WXIBF)

Tipranks - Tipranks - Wed Aug 27, 2025

In a report released today, Nico Chen from DBS maintained a Hold rating on Wuxi Biologics (Cayman), with a price target of HK$36.00. The company’s shares closed last Friday at $4.20.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Chen covers the Healthcare sector, focusing on stocks such as Sanofi, Wuxi Biologics (Cayman), and Amgen. According to TipRanks, Chen has an average return of 6.6% and a 59.65% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wuxi Biologics (Cayman) with a $4.48 average price target, which is a 6.67% upside from current levels. In a report released on August 21, Goldman Sachs also maintained a Hold rating on the stock with a HK$29.30 price target.

See today’s best-performing stocks on TipRanks >>

WXIBF market cap is currently $17.16B and has a P/E ratio of 29.35.

Read More on WXIBF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).